Mithradote Bio — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Mithradote Bio is a private, pre-revenue biotech focused on a critical unmet need in public health and personal safety: the prevention of drug-facilitated sexual assault. Its lead candidate, M-101, is a sublingual pan-antidote intended to counteract benzodiazepines, Z-drugs, and other GABA agonists used in drink-spiking. The company is in the pre-clinical or early development stage, building its team and technology to bring a portable, fast-acting countermeasure to market. This positions Mithradote at the intersection of biotechnology, harm reduction, and women's health.

Drug-facilitated sexual assault preventionSubstance overdose reversal

Technology Platform

Novel sublingual formulation platform for rapid delivery of a pan-antidote targeting GABA receptor agonists (benzodiazepines, Z-drugs).

Opportunities

Addresses a massive, unmet global need for a personal safety tool against drug-facilitated crimes, with no direct competition.

The product could create an entirely new category in OTC or prescription pharmacotherapy for harm reduction and empowerment, with potential for expansion into other overdose reversal settings.

Risk Factors

High scientific risk in developing a safe and effective broad-spectrum antidote; uncertain and novel regulatory pathway for a self-administered emergency product; significant commercialization challenges including adoption, pricing, distribution, and potential liability.

Competitive Landscape

There are currently no FDA-approved self-administered antidotes for drink-spiking drugs. The closest analogs are hospital-administered flumazenil (for benzodiazepine overdose) and naloxone (for opioids), but these are not designed or approved for this specific use case. Mithradote's primary competition is the status quo of no pharmacological intervention, positioning it as a first-in-category pioneer if successful.

More companies in Small Molecule Drugs →More companies in United States →